AstraZeneca’s ovarian cancer tablets pass Phase III SOLO-2 trial
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…
Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…
Novartis’s Q3 2016 net income $10,9B shorter than last year
Allergan successfully completed its tender offer to purchase …
Bangladesh-based Beximco, the largest country’s pharmaceutcals exporter, has received its second US FDA …
Astellas Pharma and Pfizer have announced the FDA approved a supplemental New …
The US FDA has approved Merck’s Zinplava (bezlotoxumab) Injection 25 mg/mL, which …
GlaxoSmithKline has submitted a Biologics License Application (BLA) for its candidate shingles vaccine, ShingrixTM, to the United States Food and Drug Administration (FDA).
Faron Pharmaceuticals (Faron), the clinical stage biopharmaceutical company, has recruited the first patient in the Japanese Phase III pivotal clinical trial for the…
Nanobiotixa has announced that its Asia-Pacific partner, PharmaEngine, has dosed its first patient in a new Phase I/II trial in patients with head and neck cancers patient receiving radiotherapy plus chemotherapy, this October.